Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (2114)	6/7/2004 4:47:50 PM
From: Icebrg	Read Replies (1) of 3044

Millennium Pharmaceuticals "neutral" Monday, June 07, 2004 11:20:13 AM ET Robert W. Baird NEW YORK, June 7 (New Ratings) — Analysts at Robert W Baird maintain their "neutral" rating on Millennium Pharmaceuticals, Inc (MLNM.NAS). The target price is set to $17. In a research note published this morning, the analysts mention that Millennium Pharmaceuticals’ Velcade product has exhibited promising survival and response rate data in the treatment of early-stage multiple myeloma and non-small cell lung cancer. Robert W Baird expresses its concern, however, regarding the disappointing results of Velcade mono-therapy in metastatic breast cancer and colorectal cancer.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next